Illumina, Inc. (ILMN) Director Jay T. Flatley Sells 20,000 Shares
Illumina, Inc. (NASDAQ:ILMN) Director Jay T. Flatley sold 20,000 shares of the business’s stock in a transaction dated Tuesday, December 5th. The stock was sold at an average price of $212.55, for a total transaction of $4,251,000.00. Following the sale, the director now directly owns 505,980 shares in the company, valued at $107,546,049. The sale was disclosed in a legal filing with the SEC, which is available through this link.
Shares of Illumina, Inc. (ILMN) traded up $0.69 on Thursday, reaching $214.67. 682,331 shares of the company were exchanged, compared to its average volume of 955,885. Illumina, Inc. has a twelve month low of $120.00 and a twelve month high of $230.72. The firm has a market cap of $31,510.00, a price-to-earnings ratio of 61.71, a P/E/G ratio of 3.49 and a beta of 0.79. The company has a debt-to-equity ratio of 0.41, a quick ratio of 3.73 and a current ratio of 4.22.
Illumina (NASDAQ:ILMN) last announced its earnings results on Tuesday, October 24th. The life sciences company reported $1.11 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.99 by $0.12. Illumina had a net margin of 30.34% and a return on equity of 19.42%. The firm had revenue of $714.00 million for the quarter, compared to analyst estimates of $692.77 million. During the same quarter in the prior year, the business posted $0.97 EPS. The business’s revenue was up 17.6% compared to the same quarter last year. analysts anticipate that Illumina, Inc. will post 3.75 earnings per share for the current year.
Several equities research analysts have commented on the stock. BidaskClub cut shares of Illumina from a “buy” rating to a “hold” rating in a research report on Wednesday. Barclays reissued an “equal weight” rating and set a $150.00 price target on shares of Illumina in a research report on Wednesday, August 9th. Vetr upgraded shares of Illumina from a “hold” rating to a “buy” rating and set a $209.78 price objective on the stock in a research note on Wednesday, August 9th. Goldman Sachs Group restated a “neutral” rating and set a $200.00 price objective on shares of Illumina in a research note on Tuesday, September 26th. Finally, Canaccord Genuity restated a “buy” rating and set a $230.00 price objective (up from $215.00) on shares of Illumina in a research note on Thursday, October 12th. One research analyst has rated the stock with a sell rating, nine have issued a hold rating and fourteen have given a buy rating to the stock. The company currently has an average rating of “Buy” and an average price target of $201.98.
Illumina Company Profile
Illumina, Inc (Illumina) is a provider of sequencing- and array-based solutions for genetic analysis. The Company operates through two segments: Core Illumina and the consolidated variable interest entities (VIEs), which include the activities of GRAIL, Inc (GRAIL) and Helix Holdings I, LLC (Helix). Core Illumina consists of its core operations.
Receive News & Ratings for Illumina Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina Inc. and related companies with MarketBeat.com's FREE daily email newsletter.